Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples